161 Views | 70 Downloads
See publication for a full list of authors.
Acknowledgments: The authors would like to thank Dr. Michelle M. Mielke for her helpful comments and feedback on early drafts of this manuscript.
Disclosures: L.S.S. reports being an editor on the Cochrane Collaboration Dementia and Cognitive Improvement Group, which oversees systematic reviews of drugs for cognitive impairment and dementia.
LSS also received a grant from the Alzheimer’s Association for a registry for dementia and cognitive impairment trials; he is also in receipt of grant or research support from Baxter, Elan Pharmaceuticals, Johnson & Johnson, Eli Lilly, Myriad, Novartis, and Pfizer. He has served as a consultant for or received consulting fees from Abbott Laboratories, AC Immune, Allergan, Allon, Alzheimer Drug Discovery Foundation, AstraZeneca, Bristol-Myers Squibb, Elan, Eli Lilly, Exonhit, Forest, GlaxoSmithKline, Ipsen Pharmaceuticals, Johnson & Johnson, Lundbeck, Myriad, Medavante, Medivation, Merck, Merz, Novartis, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, Schwabe, Toyama, and Transition Therapeutics.
L.N.G. reports serving on the Phillips Life Line Falls Advisory Board.
D.S.M. is a full time employee of Bracket .
C.G.L has received grant support (research or CME) from NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan, Functional Neuromodulation Inc.; has served as consultant/advisor for Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, NFL Players Association, NFL Benefits Office, Avanir, Zinfandel; and received honorarium or travel support from Pfizer, Forest, Glaxo-Smith Kline, and Health Monitor.
Y.E.G. was supported by NIMH grant K01-MH68351, NIA grant U01-AG006786 (the Mayo Clinic Study of Aging), National Center for Research Resources grant RR024150 (Mayo Clinic CTSA [Career Transition Award]), the Robert Wood Johnson Foundation (Harold Amos Scholar), and the European Union Regional Development Fund (Project FNUSA-ICRC: CZ.1.05/1.1.00/02.0123).
L.N.G. was supported by NIMH grants R24-MH074779, R01-MH079814, and RC1-MH090770-01, and Alzheimer’s Association grant IIRG-07-28686;
C.G.L. was supported by the Johns Hopkins Alzheimer’s Disease Research Center (P50-AG005146).
© 2013 The Alzheimer¢s Association. All rights reserved.